INC Research, a therapeutically focused CRO based in Raleigh, N.C., has opened a facility in Seoul, South Korea to manage the growing demand for world-class clinical development programs.
"The South Korean government has renewed its focus on healthcare and clinical development leading to a dramatic increase in the opportunities for biopharmaceutical companies' drug development programs," said Kelvin Logan, PhD, president of Asia/Pacific, INC Research. "Our expanded team is equipped to help customers take advantage of the benefits of conducting clinical trials in this region, while navigating through the developing regulatory environment and leveraging support resources."
The company's South Korean team is primarily focused on study start-up and clinical operations activities around key therapeutic areas. The new office is located in Gangnam-gu, Seoul, in the central business district with easy access to client and business partners and will be managed by Dr. Jessica Liu, general manager, and Lee Sun-Mee, associate director of clinical operations and site head.
INC Research provides phase I to IV clinical development services in the Asia/Pacific region with extensive coverage across China, India, Australia, Singapore, Philippines, South Korea, Taiwan, Hong Kong, Malaysia, Thailand and New Zealand. The company has the broad regional presence, therapeutic expertise, operational excellence and ability to apply international insights to local projects to meet the needs of drug developers.